Category: Technology

Categories
Local News Science Technology

Bristol Myers Squibb receives positive CHMP opinion recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for treatment of mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer after prior chemotherapy

Application based on positive results from the Phase 2 CheckMate -142 trial demonstrating a durable clinical benefit in the Opdivo plus Yervoy cohort

Recommendation from the CHMP represents the first positive opinion in the EU for a dual immunotherapy in colorectal cancer

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #CHECKMATE—Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) after prior fluoropyrimidine-based combination chemotherapy. The opinion was based on data from the Phase 2 CheckMate -142 trial. The European Commission (EC), which is authorized to approve medicines for the European Union (EU), will now review the CHMP recommendation.

“Metastatic colorectal cancers with mismatch repair deficient or microsatellite instability-high biomarkers can be difficult to treat, and patients who progress on or after first-line chemotherapy still face a great unmet need despite overall progress in the field,” said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. “The CHMP’s positive opinion further supports our goal to advance rational combinations that target distinct but complementary immune pathways. We look forward to the EC’s decision later this year and are excited by the potential positive impact this novel combination could have for patients in need throughout the EU.”

Opdivo plus Yervoy received approval from the U.S. Food and Drug Administration (FDA) in July 2018 for the treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan. Opdivo plus Yervoy was also approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in September 2020 for the treatment of MSI-H unresectable, advanced or recurrent colorectal cancer progressing after cancer chemotherapy.

About CheckMate -142

CheckMate -142 included a multicenter, non-randomized, open-label cohort investigating Opdivo plus Yervoy in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC) whose disease had progressed during or after prior treatment with fluoropyrimidine, oxaliplatin and irinotecan.

In this combination cohort, patients received Opdivo 3 mg/kg with Yervoy 1 mg/kg every three weeks for four doses, followed by Opdivo 3 mg/kg as a single agent every two weeks until disease progression, death, or unacceptable toxicity. Efficacy outcome measures included objective response rate (ORR) as assessed by blinded independent central review using Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and duration of response (DoR).

About dMMR or MSI-H Colorectal Cancer

Colorectal cancer (CRC) is a cancer that develops in the colon or the rectum, which are part of the body’s digestive or gastrointestinal system. Globally, CRC is the third most commonly diagnosed cancer in the world. In 2020, it is estimated that there were approximately 1,931,000 new cases of the disease and that it will be the second leading cause of cancer-related deaths among men and women combined.

Mismatch repair deficiency (dMMR) occurs when the proteins that repair mismatch errors in DNA replication are missing or non-functional, leading to microsatellite instability-high (MSI-H) tumors. Approximately 5% of metastatic CRC patients have dMMR or MSI-H tumors. Metastatic CRC patients with these biomarkers are less likely to benefit from conventional chemotherapy and typically have a poor prognosis.

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan, and China. In October 2015, the Company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

About Yervoy

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. On March 25, 2011, the U.S. Food and Drug Administration (FDA) approved Yervoy 3 mg/kg monotherapy for patients with unresectable or metastatic melanoma. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries. There is a broad, ongoing development program in place for Yervoy spanning multiple tumor types.

INDICATIONS

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of patients with intermediate or poor risk advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

OPDIVO® (nivolumab) is indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

Immune-Mediated Pneumonitis

OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune-mediated pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.9%), and Grade 2 (2.1%). In HCC patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 10% (5/49) of patients. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%). In NSCLC patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, immune-mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.

In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12).

Immune-Mediated Colitis

OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated colitis occurred in 25% (115/456) of patients, including Grade 4 (0.4%), Grade 3 (14%) and Grade 2 (8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade 2 (3.7%).

In a separate Phase 3 trial of YERVOY 3 mg/kg monotherapy, immune-mediated colitis occurred in 12% (62/511) of patients, including Grade 3-5 (7%) and Grade 2 (5%).

Immune-Mediated Hepatitis and Hepatotoxicity

OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%), and Grade 2 (0.4%). In patients receiving OPDIVO monotherapy in Checkmate 040, immune-mediated hepatitis requiring systemic corticosteroids occurred in 5% (8/154) of patients. In patients receiving OPDIVO 1 mg/ kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 15% (70/456) of patients, including Grade 4 (2.4%), Grade 3 (11%), and Grade 2 (1.8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade 2 (0.4%).

In a separate Phase 3 trial of YERVOY 3 mg/kg monotherapy, immune-mediated hepatitis occurred in 4.1% (21/511) of patients, including Grade 3-5 (1.6%) and Grade 2 (2.5%).

OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.

Immune-Mediated Endocrinopathies

OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.

In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1% (20/1994), including Grade 3 (0.4%) and Grade 2 (0.6%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, adrenal insufficiency occurred in 8% (35/456), including Grade 4 (0.2%), Grade 3 (2.4%), and Grade 2 (4.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade 3 (2.5%), and Grade 2 (4.1%). In patients receiving OPDIVO and cabozantinib, adrenal insufficiency occurred in 4.7% (15/320) of patients, including Grade 3 (2.2%) and Grade 2 (1.9%).

In patients receiving OPDIVO monotherapy, hypophysitis occurred in 0.6% (12/1994) of patients, including Grade 3 (0.2%) and Grade 2 (0.3%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, hypophysitis occurred in 9% (42/456), including Grade 3 (2.4%) and Grade 2 (6%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypophysitis occurred in 4.4% (29/666) of patients, including Grade 4 (0.3%), Grade 3 (2.4%), and Grade 2 (0.9%).

In patients receiving OPDIVO monotherapy, thyroiditis occurred in 0.6% (12/1994) of patients, including Grade 2 (0.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, thyroiditis occurred in 2.7% (22/666) of patients, including Grade 3 (4.5%) and Grade 2 (2.2%).

In patients receiving OPDIVO monotherapy, hyperthyroidism occurred in 2.7% (54/1994) of patients, including Grade 3 (<0.1%) and Grade 2 (1.2%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, hyperthyroidism occurred in 9% (42/456) of patients, including Grade 3 (0.9%) and Grade 2 (4.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hyperthyroidism occurred in 12% (80/666) of patients, including Grade 3 (0.6%) and Grade 2 (4.5%).

In patients receiving OPDIVO monotherapy, hypothyroidism occurred in 8% (163/1994) of patients, including Grade 3 (0.2%) and Grade 2 (4.8%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, hypothyroidism occurred in 20% (91/456) of patients, including Grade 3 (0.4%) and Grade 2 (11%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypothyroidism occurred in 18% (122/666) of patients, including Grade 3 (0.6%) and Grade 2 (11%).

In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9% (17/1994) of patients, including Grade 3 (0.4%) and Grade 2 (0.3%), and 2 cases of diabetic ketoacidosis. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, diabetes occurred in 2.7% (15/666) of patients, including Grade 4 (0.6%), Grade 3 (0.3%), and Grade 2 (0.9%).

In a separate Phase 3 trial of YERVOY 3 mg/kg monotherapy, Grade 2-5 immune-mediated endocrinopathies occurred in 4% (21/511) of patients. Severe to life-threatening (Grade 3-4) endocrinopathies occurred in 9 (1.8%) patients. All 9 patients had hypopituitarism, and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism. Six of the 9 patients were hospitalized for severe endocrinopathies. Moderate (Grade 2) endocrinopathy occurred in 12 patients (2.

Contacts

Bristol Myers Squibb

Media Inquiries:
Media@BMS.com

Investors:
Tim Power

609-252-7509

timothy.power@bms.com

Nina Goworek

908-673-9711

nina.goworek@bms.com

Read full story here

Categories
Business Technology

AM Best to host webinar on AM Best’s directors & officers insurance

OLDWICK, N.J. — (BUSINESS WIRE) — AM Best will host a complimentary webinar on Thursday, May 27, 2021, at 2:00 p.m. (EDT). Sridhar Manyem and David Blades of AM Best will join industry experts to discuss emerging trends in the directors and officers insurance market. Topics covered will include rising litigation costs, a hardening pricing environment and the impact of special-purpose acquisition companies (SPAC), environmental, social and governance (ESG) and cyber for the market.

Register now: www.ambest.com/webinars/DO21.

Panelists include:

  • David Blades, associate director, AM Best;
  • Uri Dallal, managing director, AON;
  • Brian Finlay, senior vice president, Trans Re; and
  • Sridhar Manyem, director, industry research, AM Best.

Attendees can submit questions during registration or by emailing webinars@ambest.com. The event will be streamed in video and audio formats, and playback will be available to registered viewers shortly after the event.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2021 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Christopher Sharkey

Manager, Public Relations

+1 908 439 2200, ext. 5159

christopher.sharkey@ambest.com

Jim Peavy

Director, Communications

+1 908 439 2200, ext. 5644

james.peavy@ambest.com

Categories
Business Technology

Samsung unveils National Winners in $2 Million STEM competition for innovations that Address urban sustainability, social justice and isolation-induced depression amid COVID-19

 

 

Schools in Michigan, Pennsylvania and Texas recognized for tackling pressing issues in 11th annual Samsung Solve for Tomorrow Contest

 

RIDGEFIELD PARK, N.J. — (BUSINESS WIRE) — Samsung Electronics America, Inc. announced today the three grand prize National Winners in the 11th annual Samsung Solve for Tomorrow Contest – a $2 million* national competition that challenges public school students in grades 6-12 to use STEM (science, technology, engineering and math) skills to address real-world change in their communities. Revealed during a livestream virtual celebration event, each National Winner school will receive $130,000 in technology and supplies to meet the needs of their classrooms.

 

Three National Winners were selected following a virtual pitch event where students presented their STEM projects to a panel of judges. From urban sustainability to social justice and isolation-induced depression from COVID-19, each National Winner used problem-based learning to respond to an issue of national importance impacting their local communities. Throughout the academic school year – while learning in virtual and hybrid environments – students and teachers forged new pathways using creativity and innovation to create their STEM solutions.

 

“We are in awe of the resilient, bright young minds who remained nimble despite a challenging school year. Met with virtual and hybrid learning environments, their ability to empathetically approach three of the most critical issues facing our society and each transform an idea into a STEM innovation is nothing short of incredible,” said Ann Woo, Senior Director of Corporate Citizenship at Samsung Electronics America. “Tackling social justice, the pandemic and health of our planet, these are the problem-solvers and changemakers who build hope for our future.”

 

The three National Winners in the 11th annual Samsung Solve for Tomorrow Contest and their grand prize-winning STEM innovations are:

 

1. Hope of Detroit Academy – Detroit, Michigan

The student’s local community in southwest Detroit faces excessive amounts of garbage, used tires left in open spaces and unsecured abandoned homes. In Detroit, a significant percentage of housing parcels in the city are vacant, and abandoned lots are prevalent throughout residential areas. The students created an app – the Green Warrior – that tracks these sites and reports them to local community organizations that help lead clean-up efforts. For example, Green Tree Plastics will help collect plastic from abandoned sites and convert it into park benches, and Cass Community Social Services will help pick up and recycle tires.

View Hope of Detroit Academy’s project video here: https://youtu.be/hfY23Gzbmek

 

2. Northwest Pennsylvania Collegiate Academy – Erie, Pennsylvania

After witnessing recent events locally and nationally where people were challenged while advocating for social justice, the students recognize that many people fear encounters with law enforcement during protests, rallies or traffic stops. Wanting to be allies and protect the civil rights of people using their voice in potentially threatening situations, the students created a voice-activated mobile app that turns the phone into a body camera or dash cam to record the events and interactions.

In addition to being named a National Winner, Northwest Pennsylvania Collegiate Academy has also been named the Samsung Employee Choice Award Winner,winning an additional $15,000.

View Northwest Pennsylvania Collegiate Academy’s project video here: https://youtu.be/bqrckcWFrjk

 

3. Porter High School – Porter, Texas

As many as one in four elderly individuals report having anxiety or depression amid the COVID-19 pandemic, and a study by the CDC showed that isolation and loneliness are associated with a 50% increased risk of developing dementia, a 32% increased risk of stroke, and a nearly fourfold increased risk of death among heart failure patients. To combat isolation-induced depression and loneliness, students created an app-website combo, Gen-Bridge, that enables students and others to connect in various ways – including video calls, games and more – with seniors residing in assisted living facilities.

 

View Porter High School’s project video here: https://youtu.be/camCTwrC2EY

 

Students and teachers from each National Winner school have met with local representatives to discuss their respective projects.

 

In addition to the three National Winners, Tulare Union High School in Tulare, California, and Tucker Middle School in Tucker, Georgia, were named Community Choice Winners for generating the most social media votes for their inventions addressing traffic collisions and human trafficking, respectively. These two schools will each receive an additional $15,000 in technology on top of $65,000 in technology for being named National Finalists in this year’s competition.

 

The three National Winners, two Community Choice Award Winners and Samsung Employee Choice Award Winner were revealed in a virtual celebration event, which brought together dozens of students and teachers from the 10 National Finalist schools. The event included remarks from Samsung executives and employee mentors as well as Solve for Tomorrow alumni and can be seen here. The event also included a guest appearance by artist and animator, Danny Casale.

 

Anchored in Samsung’s guiding vision of ‘Together for Tomorrow! Enabling People’, Solve for Tomorrow launched in 2010 to encourage innovative thinking, creative problem-solving and teamwork to discover and nurture social innovation ideas aimed at resolving society’s most pressing problems. What began as an environment-focused essay contest has transformed into a problem-based learning initiative that fosters critical thinking and creative problem solving. Since its inception, the Samsung Solve for Tomorrow Contest has awarded $18 million in Samsung technology and classroom materials to more than 2,500 public schools in the United States.

 

To learn more about the contest and this year’s winners, please visit: ​www.samsung.com/solve or follow us at on Instagram @solvefortomorrow. For official rules and judging criteria, click here.

 

*Prize is based on an estimated retail value. | Not open to the general public: No purchase necessary to enter or win. Open to employees at eligible schools in the fifty (50) United States/DC twenty-one (21) years of age or older. To enter/official rules: visit www.Samsung.com/Solve to complete the application form. | The school is responsible for ensuring the proper handling and security of all data potentially shared and/or collected as part of their project. Samsung takes privacy very seriously and encourages all Semi-Finalists to consider how information that is part of their project is being handled. | The school is responsible for ensuring safety, security, bias and privacy matters related to artificial intelligence (AI) as part of their project. Samsung takes privacy very seriously and encourages all Semi-Finalists to consider all safety precautions related to their projects throughout development.

 

About Samsung Electronics America, Inc.

Headquartered in Ridgefield Park, N.J., Samsung Electronics America, Inc. (SEA), is a leader in mobile technologies, consumer electronics, home appliances and enterprise solutions. A wholly owned subsidiary of Samsung Electronics Co., Ltd., SEA is pushing beyond the limits of today’s technology and providing consumers and organizations with a portfolio of groundbreaking products and services across mobile devices, connected appliances, home entertainment, 5G networks and digital solutions. To discover more about Samsung, please visit www.samsung.com. For the latest Samsung News please visit news.samsung.com/us and follow us @SamsungNewsUS.

Contacts

Olivia Gust

Allison+Partners for Samsung

1-503-528-6768

SamsungSFT@allisonpr.com

Categories
Business Technology

NICE Enlighten AI recognized with Product of the Year Award for enabling organizations to meet and exceed next-gen customer expectations

CUSTOMER Magazine honors NICE Enlighten AI as an innovative CX solution and highlights dedication to quality that benefits the overall customer experience while driving ROI

 

HOBOKEN, N.J. — (BUSINESS WIRE) — #NICE—NICE (Nasdaq: NICE) today announced that NICE Enlighten AI for Customer Satisfaction has been named a winner of the 2021 CUSTOMER Magazine Product of the Year Award by integrated media company TMC. Highlighting products that enable their clients to meet and exceed customers’ expectations, the award recognizes organizations that are advancing the call center, CRM and teleservices industries one solution at a time.

Barry Cooper, President, NICE Workforce and Customer Experience Group, said, “We are in the business of empowering organizations to boost brand loyalty by enabling every customer’s experience to be personalized and contextual. As organizations prioritize the delivery of next-gen CX, we’re proud to shine a light on how embedding smart AI everywhere helps measurably boost customer satisfaction and employee engagement.”

NICE Enlighten AI for Customer Satisfaction enables businesses of all sizes to proactively make every customer interaction exceptional. NICE Enlighten AI interprets and objectively measures the human behaviors proven to influence customer satisfaction. Out of the box Enlighten AI behavior models accurately and immediately score nine specific agent behaviors, such as demonstrating ownership, being empathetic, questioning effectively and more, as well as customer sentiment on every interaction and presents them on the agent and manager’s dashboards. As a result, agents can proactively adapt and self-improve their behavior in real-time while managers can identify coaching opportunities to drive longer term development.

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media Contact
Christopher Irwin-Dudek, +1 201 561 4442, ET, chris.irwin-dudek@nice.com

Investors
Marty Cohen, +1 551 256 5354, ET, ir@nice.com

Categories
Business Technology

Precision Spine® reaches milestone with the Reform® Modular Pedicle Screw System

 

PARSIPPANY, N.J. — (BUSINESS WIRE) — The Reform® Modular Pedicle Screw System, first introduced by Precision Spine in April 2016, today reaches a monumental milepost, its 30,000th modular screw implantation. This historic milestone is most impressive when highlighted by the fact that there have been no reported dissociations to date.

 

The Reform® Modular Pedicle Screw System provides surgeons with increased flexibility, versatility, and visibility to meet the varying requirements of degenerative and trauma procedures. The cobalt chrome and titanium tulips are available in both 5.5 and 4.75mm sizes, with standard and reduction options. The system features Tru-Lock Technology that allows the tulip to be attached with a consistent attachment force, as well as a helpful audible click and tactile feel to confirm attachment. The titanium modular cannulated and non-cannulated screws feature a minimally tapered, triple lead thread, as well as a self-starting aggressive screw tip and enlarged T25 drive feature ─ the combination of which delivers more immediate, secure bone engagement and maximum control during insertion. The system’s modularity is intended to help increase the surgeon’s visibility in order to permit more thorough decortication of the surrounding fusion bed. A full complement of offset connectors, dominoes, hooks, and cross connectors increases procedure flexibility.

 

“The system’s modular design greatly enhances O.R. versatility and efficiency,” said Vikram Udani, M.D., “assisting surgeons with intraoperatively assembling a construct that achieves immediate bone purchase, with a pull-out strength that provides optimal security.”

 

“We are pleased and proud to document this event in our company annals,” said Chris DeNicola, the company’s Chief Operating Officer, “as it is further evidence of our continuing mission to provide patients and surgeons worldwide with safe and effective solutions for complex spinal pathologies. We view this milestone as validation of the great trust placed in the company by our distribution partners and the surgeons they serve and support.”

 

About Precision Spine

Precision Spine, Inc. is a privately held company headquartered in Parsippany, NJ, with manufacturing facilities in Pearl, MS. Precision Spine is dedicated to providing innovative, quality spine products that are made in the USA, and designed to help treat serious orthopedic medical conditions in a cost-effective manner. For more information, visit www.precisionspineinc.com.

Contacts

Chris DeNicola, Chief Operating Officer: chris.denicola@precisionspineinc.com

Categories
Science Technology

Oncology and hematology specialists, P.A. and Deep Lens partner to integrate clinical trial matching solution VIPER™ into network, expanding offering to patients

COLUMBUS, Ohio & MORRISTOWN, NJ. — (BUSINESS WIRE) — #clinicalresearch—Deep Lens and Oncology and Hematology Specialists, P.A. today announced that they will partner to deploy artificial-intelligence (AI)-based trial matching solution, VIPER™, into the New Jersey-based cancer network. The Deep Lens’ VIPER platform uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. Oncology and Hematology Specialists, P.A. is one of the largest cancer care networks in Northern New Jersey, serving patients across Morris county with offices in Morristown and Mountain Lakes. The cancer center utilizes Cardinal Health Specialty Solutions’ distribution and technology services, and was one of the first sites to integrate VIPER into their network since the launch of Cardinal Health™ Navista™ TS. Navista TS is a comprehensive and integrated suite of oncology-focused tech solutions designed to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care. VIPER is a key component of the Navista TS offering.

“Our practice has always focused on adopting and providing the newest, most innovative approaches to cancer care to our patients — from cutting-edge therapeutics to supportive services and wellness events. We are delighted to further expand this offering to our patient community by broadening our clinical trial program through the deployment of VIPER,” said Fazal Bari, M.D. at Oncology and Hematology Specialists, P.A. “VIPER will not only assist our staff in identifying the right trials for our patients, but the larger partnership with Deep Lens will assist in bringing more precision-based trials to our network, thereby giving more opportunities for our patients to access emerging new drugs in development.”

It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent. Limited site capacity and resources play a role in the challenge to recruit and enroll, as well as low patient engagement. All of these challenges have been magnified by the current global pandemic. VIPER automates the clinical trial screening process and seamlessly matches patients — at the time of diagnosis — to appropriate trials through the ingestion and analysis of customized genomic data, electronic medical records and pathology data.

“We are delighted to partner with the Oncology and Hematology Specialists’ team to enhance the comprehensive suite of cancer care resources they offer to their patient community,” said Greg Andreola, chief revenue officer at Deep Lens. “We are confident that the inclusion of VIPER will not only help more cancer patients in Northern New Jersey access potentially life-changing new therapies, but it will position the cancer center prominently as a leading clinical research institution. We look forward to helping Oncology and Hematology Specialists optimize the stellar care they are already providing to the patient community in New Jersey.”

Deep Lens’ VIPER will be integrating directly to the Oncology and Hematology Specialists, P.A.’s EMR (Flatiron Health’s OncoEMR), molecular data feeds (Foundation Medicine, Caris Life Sciences and Guardant Health), pathology and imaging feeds to automatically identify qualified patients for clinical trials. Like Oncology and Hematology Specialists, P.A., any practice that utilizes OncoEMR can easily integrate VIPER and all other Deep Lens screening services free of charge.

About Oncology Hematology Specialists, P.A.

Oncology and Hematology Specialists P.A. was founded in 1976 and is one of the leading cancer care facilities in New Jersey. The practice provides care for more than 100 patients per day in two convenient, community-based locations, Morristown and Mountain Lakes. The talented healthcare provider team at Oncology and Hematology Specialists, P.A. manages diagnostic, treatment, nutritional, and prescription-based services for most patients. For more information, please visit www.ohsnj.com.

About Deep Lens

Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows that combine lab, EMR, and genomic data to match cancer patients to clinical trials and precision therapies at the time of diagnosis, accelerating recruitment and compressing study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies. For more information, visit www.deeplens.ai.

Contacts

Deep Lens media contact: Adrienne Kemp, media@deeplens.ai, +1 (949) 922-0801

Oncology Hematology Specialists, P.A. contact: contact@ohsnj.com

Categories
Science Technology

Diaceutics and LGC SeraCare partnership expands diagnostic commercialization solutions enabled by Global DXRX platform

  • LGC SeraCare joins Diaceutics’ DXRX Network of industry leading service providers to provide end to end solution for development and commercialization of precision medicine diagnostics
  • DXRX platform already provides access to laboratory testing solutions from partners including Targos Molecular Pathology, Histocyte Laboratories, CPQA-ACQP, EMQN CIC, NordiQC, UKNEQAS and Alva10 Dx
  • Partnership introduces additional types of test reference materials and technologies to platform offering including Seraseq™ FFPE Tumor Fusion RNA Reference Material v4 and Seraseq™ FFPE NTRK Fusion RNA Reference Material available in 132 countries
  • Global DXRX platform enables pharmaceutical companies to achieve seamless testing for precision medicines ahead of market launch using best-in-class testing solutions

 

PARSIPPANY, N.J. — (BUSINESS WIRE) — Diaceutics PLC (AIM:DXRX) today announces a new partnership with LGC SeraCare (“SeraCare”), the US-based manufacturer of diagnostic test reference standard controls. The partnership sees LGC SeraCare join the Diaceutics DXRX Network, the world’s first end-to-end digital solution for the development and commercialization of precision medicine diagnostics, expanding the range of test standardization solutions available via the platform.

DXRX has been designed to accelerate diagnostic accuracy to ensure that precision medicines are correctly prescribed to eligible patients at the right time in the treatment journey, securing the best possible outcomes. LGC SeraCare joins a growing network of industry leaders in precision medicine diagnostics who use the platform’s technology to collaborate digitally to enable seamless diagnostic testing for precision medicines, ahead of market launch.

Existing laboratory testing solutions partners on the DXRX platform include Targos Molecular Pathology, Histocyte Laboratories, CPQA-ACQP, EMQN CIC, NordiQC, UKNEQAS and Alva10 Dx. This new partnership introduces additional types of test reference materials and technologies to the platform including Seraseq™ FFPE Tumor Fusion RNA Reference Material v4 and Seraseq™ FFPE NTRK Fusion RNA Reference Material, available in 132 countries.

By providing these critical technologies to the DXRX platform, both LGC SeraCare and Diaceutics will be able to advance their goal of enabling greater adoption of precision medicine by enabling all laboratories to provide consistently high quality testing using reference material to validate their test system, faster.

Alpa Shah, Senior Director Sales, Clinical Genomics – LGC SeraCare commented on the partnership:

“As a provider of innovative technologies that leverage our deep experience and unique perspective to enable the promise of precision medicine, we are delighted to be joining what is a network of true innovators in the industry. Our unwavering commitment to serve and empower clinical and research laboratories, as well as in vitro diagnostics developers is aligned with DXRX as a platform solution which places the laboratory at the centre of a precision medicine network and enables the diagnostic industry to extract more value from Precision Medicine. We look forward to the continued expansion of our offering via the platform and the business development opportunities it brings to SeraCare.”

DXRX Network Advisor, Kenneth J. Bloom, Chief Medical Officer of Advanced Pathology and Genomic Services, Konica Minolta Precision Medicine commented:

“As the post-Covid testing landscape emerges with new complexity, it is now more critical than ever that pharma are collaborating digitally with key stakeholders in the testing supply chain to guarantee diagnostic testing accuracy. It is fantastic to see this collaboration which is an important step in getting every patient the treatment they deserve.”

Contacts

Enquiries:
Alma PR
Caroline Forde

Robyn Fisher

Kieran Breheny

+44 (0)20 3405 0205

diaceutics@almapr.co.uk

Categories
Science Technology

Velodyne Lidar launches breakthrough Intelligent Infrastructure Solution

Rutgers University Selects Velodyne’s Solution as Cornerstone Technology for New Jersey Department of Transportation Smart City Project

 

SAN JOSE, Calif. — (BUSINESS WIRE) — #VelodyneLidar—Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today launched its Intelligent Infrastructure Solution designed to solve some of the most challenging and pervasive infrastructure problems. This new solution combines Velodyne’s award-winning lidar sensors and Bluecity’s powerful artificial intelligence (AI) software to monitor traffic networks and public spaces. It generates real-time data analytics and predictions, helping to improve traffic and crowd flow efficiency, advance sustainability and protect vulnerable road users.


The Intelligent Infrastructure Solution is available now exclusively from Velodyne. It is already deployed in multiple North America cities, including in Quebec and British Columbia, with upcoming installations in New Jersey and more deployments expected across the United States.

Velodyne also announced a sales agreement with Rutgers Center for Advanced Infrastructure and Transportation (CAIT) to deploy its Intelligent Infrastructure Solution equipped with Velodyne’s Alpha Prime™ lidar sensors. CAIT will install the solution at multiple intersections in New Brunswick, New Jersey as part of the Middlesex County – Smart Mobility Testing Ground (MC-SMTG) project in collaboration with the New Jersey Department of Transportation (NJDOT). The project will serve as a testbed for mobility data-gathering, analysis and sharing technologies that will help implement connected and autonomous vehicle systems in the future. CAIT selected the Velodyne solution after a rigorous vetting process, in which they tested other sensor solutions and competitive lidar systems.

“The acquisition and analysis of mobility data is crucial to integrating autonomous vehicles, and creating a safer pedestrian and cycling environment,” said Dr. Ali Maher, professor and director, Rutgers Center for Advanced Infrastructure and Transportation. “Velodyne’s Intelligent Infrastructure Solution captures data on various traffic activity including vehicles, pedestrians and bicyclists in all types of environmental conditions. We envision the solution as playing a critical role in helping us create a safer environment for all road users.”

“There is a growing commitment by governments worldwide to rebuild outdated transportation infrastructure systems. Leading the way is the 2.25 trillion-dollar proposal by the Biden Administration to invest in the modernization of vehicles, roads and transit systems. As Velodyne looks at a world with connected and autonomous vehicles, we know that infrastructure will play a critical role in moving this industry forward,” said Anand Gopalan, Chief Executive Officer, Velodyne Lidar. “Our solution, powered by Bluecity’s AI-powered traffic monitoring software platform, will be key in the efforts to transform our roads and transportation infrastructure into smart cities, paving the way for a more sustainable, safer future.”

Velodyne’s Solution Transforming Infrastructure

Velodyne’s Intelligent Infrastructure Solution creates a real-time 3D map of roads and intersections, providing precise traffic monitoring and analytics. It reliably collects data in any lighting or weather condition, supporting 24/7, 365 days a year operation. The solution advances safety through multimodal analytics that detect various road users including, vehicles, pedestrians and cyclists. It can predict, diagnose and address road safety challenges, helping municipalities and other customers make informed decisions to take corrective action.

The Intelligent Infrastructure Solution is more cost-effective and easier to install than radar- and camera-based systems. This lower price point is because a single lidar sensor installed on a traffic pole can cover an entire intersection or highway section compared to radar- and camera-based systems that typically need multiple sensors to cover the same area. The solution works with Velodyne’s Alpha Prime, Ultra Puck™, Puck™ and Velarray sensors. Velodyne’s lidar sensors do not identify individuals’ facial characteristics, a growing concern for civic applications. Lidar has an advantage in privacy over camera-only systems because lidar does not record details like hair and skin color.

“Rogers collaborated with Velodyne and Bluecity on a traffic monitoring system in Kelowna, B.C., which was Canada’s first 5G smart city project,” said Neel Dayal, Senior Director, Innovation and Partnerships at Rogers Communications. “The initiative showed how this lidar-based solution can track near-misses of accidents at problematic intersections. By using the solution’s data, municipalities can do the critical work of improving roadway safety in a cost-effective and efficient way.”

“We are excited to partner with Velodyne in order to bring to market this breakthrough solution that collects and analyzes detailed traffic data about road users while preserving anonymity and trust,” said Asad Lesani, CEO at Bluecity. “We believe that Velodyne sensors are best-in-class and this solution will be a game changer for the smart city industry.”

Addressing Critical Transportation Infrastructure Challenges

Velodyne Lidar’s Intelligent Infrastructure Solution can be used for:

Safety Analytics. Velodyne’s Intelligent Infrastructure Solution near-miss analytics can be used to predict, diagnose and address road safety challenges before the next collision happens. Today’s camera-based solutions require several cameras per intersection or identified public area, which typically take longer processing times to get the final analysis. Traffic studies aren’t complete if they operate only at certain hours or under certain conditions.

Traffic Efficiency and Sustainability. Velodyne’s Intelligent Infrastructure Solution delivers reliable real-time traffic data to optimize traffic light timing based on congestion and throughput in all types of weather and lighting conditions. The solution can cover various road users, including vulnerable pedestrians and cyclists, whereas current technologies generally provide data for vehicles only. Also, lidar doesn’t require any interaction with a person’s cell phone, enabling it to accurately track people in crowded areas while preserving privacy.

Crowd Analytics. The solution can enable businesses and cities to improve revenue and infrastructure by providing foot traffic data analytics to learn about traffic patterns, congregation areas, congestion points and more. Knowing how people flow through a building and where they stop along the way is useful to designers, architects and city planners.

Vehicle to Everything (V2X) Communication. Velodyne’s Intelligent Infrastructure Solution uses extracted trajectory road user data around intersections to predict potential collisions, which can be used to warn connected vehicles via V2X communications. Vehicle manufacturers can leverage the solution’s analytics in combination with their on-board safety systems to reduce accident probability.

Emergency Services. Velodyne’s Intelligent Infrastructure Solution detects collisions and near-miss incidents in real time to provide data to emergency response services for faster dispatch in both urban and rural environments.

Environmental Protection. Velodyne’s IIS can detect wildlife crossings and help prevent collisions that often result in substantial personal, environmental and economic losses, including human injuries, fatalities, loss of wildlife and vehicle damage.

About Bluecity

Bluecity is a software company that combines artificial intelligence and lidar sensors to provide accurate, real-time traffic data for the Intelligent Transportation Systems (ITS) industry. Built by and for transportation engineers, Bluecity’s solution uses deep learning to transform raw lidar data into actionable road usage and safety information. From turning movement counts, to analysis of near misses between vehicles, pedestrians, and cyclists, their system reliably detects all road users in any weather or lighting condition. With their innovative, turnkey solution, Bluecity makes cities safer and smarter. Visit bluecity.ai for more information.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Velodyne Investor Relations
InvestorRelations@velodyne.com

Media
Codeword

Liv Allen

velodyne@codeword.com

Categories
Business Technology

Garden State MLS upgrades to Remine Pro

VIENNA, Va. — (BUSINESS WIRE) — Remine, a leading real estate technology company, announced today that Garden State MLS (GSMLS) will upgrade to the fully featured Remine Pro. GSMLS will offer Remine Pro as a complimentary member benefit to their more than 26,000 valued subscribers in the Northern New Jersey area.

Remine Pro unlocks powerful new features and places key data into the hands of real estate professionals. This innovative tool brings together MLS, public, and people records to increase agent productivity and broker business.

 

“GSMLS is proud to offer Remine Pro to our members,” said Bob Kimpland, Executive Director of GSMLS. “The upgraded features included with Remine Pro furthers our mission to provide GSMLS members with the most advantageous tools that will help to grow their businesses.”

 

“We are excited to enhance our partnership with GSMLS by providing our premier technology, Remine Pro, to its members,” explained Tim Dain, VP and GM of MLS at Remine. “Our mission at Remine is to modernize the real estate industry by providing MLS partners like GSMLS with a robust platform that revolutionizes the real estate journey and assists in developing strategic workflows.”

 

About Remine

Remine is transforming MLS software solutions. We offer a complete MLS 2.0® operating system for MLSs which includes Remine Pro (a full front-end operating system), Add/Edit, Database, and RESO Platinum API solutions. In addition, Remine offers SSO Dashboard, Docs+ Transaction Management, and MLS Website.

 

Remine serves the majority of REALTORS® in the US – over 1,000,000 real estate professionals subscribe via their MLS or Association of REALTORS®. We are headquartered in Northern Virginia with remote employees across the US and in Canada. For more information, visit info.remine.com.

 

Remine is ISO 27001 Certified.

Contacts

Remine Media Relations
Dorothy Modabberi Lewis

dorothy@remine.com
(972) 349-0918

Categories
Business Technology

Sales officially launch at new iconic address 101 West 14th Street

Developed by Gemini Rosemont; Architecture by Eran Chen of ODA New York

 

NEW YORK — (BUSINESS WIRE) — Gemini Rosemont has just announced the launch of sales for the highly-anticipated luxury residences at 101 West 14th Street, designed by esteemed architecture firm ODA New York with interiors by Whitehall Interiors. 101 West 14th features 44 unique homes, and more than half feature double-height living spaces with spacious terraces that enable indoor/outdoor living and multifaceted views of downtown’s most-desired neighborhoods: Greenwich Village and Chelsea, and beyond. The building offers one- to four-bedroom homes priced from $1.25 million. Ryan Serhant, CEO/Founder of SERHANT. is managing marketing and sales.


Architect Eran Chen, Founding Principal and Executive Director of ODA, designed this one-of-a-kind building with the highest level of execution, craftsmanship, materials and level of detail. The façade consists of a high-end unitized interlocking curtain wall of 18 ft panels of glass and aluminum designed to maximize natural light, fresh air and city views.

“The launch of sales and nearing completion of 101 West 14th emphasizes our belief in the long-term value of New York City real estate and its vibrant future,” says Scott Schubiner, Acquisitions Officer for Gemini Rosemont. “We are thrilled to present these outstanding residences to the market where our world-class team’s commitment to quality and innovation is on full display.”

The exceptional residences at 101 West 14th Street will feature motorized windows and automated concealed shades. The unique large-scale glass panels, manufactured by Custom Metalcrafters Inc., were fabricated in the Province of Treviso located in Italy’s Veneto region. Installing the double-height glass panels required the largest hoist in operation in New York City at the time.

“At 101 West 14th Street, quality of life is not measured in floor area, but in volume. This boutique building offers a tailored experience where every inch has been considered. The windows are arranged in such a way to create depth from the exterior,” says Chen. “Looking out at your surroundings, through the lens of 18 ft triple-paned glass allows residents quiet and solitude and connects you to the city in a different way. We really believe that over time this building will become a new landmark for the 14th Street corridor.”

Other state-of-the-art finishes in the homes include 7” European oak hardwood flooring and Lutron HomeWorks Automation System in select units. Beautifully appointed kitchens boast Waterfall Brazilian marble countertops, full-height marble backsplash, light rift-cut oak wood veneer lower cabinets, champagne satin glass upper cabinets, and bespoke fixtures by Signature Hardware. There are Gaggenau gas cooktops, microwaves, ovens, wine refrigerators, and Bosch dishwashers and appliances. Each residence will have an in-unit Bosch/LG washer and dryer.

Master bathrooms feature Fior Di Bosco marble floor and shower tiles, Byzantine White marble wall tiles, European oak wood veneer cabinetry, Kohler fixtures, and radiant heated floors. Secondary bathrooms will have Fior Di Bosco marble tiles, Kaldewei steel tub with porcelain, porcelain floor, and wall tiles, porcelain vanity, European oak wood veneer cabinetry, and Kohler Fixtures. Powder rooms feature full-height marble wall slabs, floating marble vanity, marble floor tiles, and a stone wall base.

Sitting atop the ground-floor retail space is a suite of luxurious amenities, including a state-of-the-art fitness center, lush courtyard, and residents-only lounge. A furnished roof deck with a sprawling outdoor kitchen is the perfect setting for entertaining.

Chelsea and Greenwich Village are two of Manhattan’s world-renowned neighborhoods combining modern cultural amenities like the Whitney, the High Line and Chelsea Market, with old-world quintessential New York brownstone streets lined with cafes, restaurants and boutiques. 101 West 14th Street is within walking distance of ample green space including Union Square, Washington Square Park, Madison Square Park and Hudson River Park. Connection to every major transit line is easy and a wide range of shops and grocers are nearby.

101 West 14th will have a full-time doorman along with private storage available for purchase. The building is slated for completion in the spring of 2021. For more information, call 646-480-7665, contact 101W14@nestseekers.com or visit: www.101west14th.com.

About Gemini Rosemont

Gemini Rosemont Development is a New York City-based subdivision of Gemini Rosemont that specializes in the ground-up development of premier residential and office properties in primary markets throughout the U.S. Gemini Rosemont Development was launched in 2017 and currently has 300,000 square feet of projects under development, with a total asset value of approximately $500M.

Gemini Rosemont is a vertically integrated real estate investment management company with an existing portfolio of over eight million square feet totaling $1.6 billion in value. Gemini Rosemont selectively targets and analyzes potential investments in top-performing, high-growth technology, creative, and New Economy-centric sub-markets. Since its inception in 1992, Gemini has sponsored 170 investment vehicles and deployed approximately $1.2 billion of equity to purchase over $3 billion of assets. Nationwide, Gemini Rosemont has delivered real estate solutions for approximately 34 million square feet of commercial real estate.

About ODA New York

ODA was founded in 2007 by Eran Chen AIA, Principal and Executive Director, Ryoko Okada, Principal and Director of Interior Architecture, and Christian Bailey, Principal and Project Director. Since its inception, it has quickly emerged as one of the most recognized firms of its generation, promptly establishing a reputation for delivering imaginative and mold-breaking designs. ODA challenges conventional perspectives of dwelling that will, over time, influence life in our cities. Our award-winning team of designers bring expertise in a range of disciplines from landscape and interior design to architecture and master planning. Our team is dedicated to creating a more equitable future through good design.

About Whitehall Interiors

Taking a holistic approach to all design, Whitehall Interiors is a Manhattan-based design firm specializing in interiors and custom furnishings. From luxury residential to commercial and hospitality new construction and renovation projects, they create unique experiences designed to inspire. As an extension of Hill West Architects, the firm takes pride in being knowledgeable through all phases of project development, from conceptual design to construction administration, to deliver high-quality, exceptional spaces for every project. A few past projects include luxury condo 91 Leonard in Manhattan; Queens’ tallest residential building Skyline Tower; and luxury rental PLG in Brooklyn.

About NestSeekers International

Nest Seekers International is a game-changing firm in the rapidly expanding global real estate marketplace. The firm’s hybrid tech & brand enabled model has inspired a new wave of thinking in the industry, and its approach to daring and unconventional marketing has elevated and revolutionized the way people think of real estate. Nest Seekers International continues to expand with 25 offices and more than 1000 team members around the globe. Based in Manhattan, London, Beverly Hills, Brooklyn, Long Island City, The Hamptons, New Jersey, Miami, the Mideast and Asia.

Contacts

Media:

Victoria Shannon

Co-Founder, August PR

victoria@augustprny.com
631.525.3394